Literature DB >> 8929158

Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study.

B G Weinshenker1, M Issa, J Baskerville.   

Abstract

BACKGROUND: The anticipated rate of short-term worsening of disability scores is the basis of power estimations in clinical trials of progressive multiple sclerosis (MS). While the clinician is most concerned in modifying the long-term outcome (eg, time to reach the Expanded Disability Status Scale [EDSS]6), the end points studied in clinical trials are those describing short-term outcome (eg, worsening of EDSS scores over 1 to 3 years). However, short-term outcome of MS may not be correlated with long-term outcome.
OBJECTIVES: To validate previously published models predicting time to EDSS 6. To establish predictors of short-term outcome of MS.
SETTING: The Ottawa, Ontario, Regional Multiple Sclerosis Clinic. PATIENTS: Two hundred fifty-nine patients were followed up prospectively by a single neurologist. MAIN OUTCOME MEASURES: Actuarial analysis of time to reach EDSS 6 and change in EDSS scores over a follow-up period of 1 to 3 years.
RESULTS: The long-term outcome in the Ottawa population was more favorable than published data from London, Ontario. Predictions of time to EDSS 6 were not strongly correlated with the degree of short-term worsening over the follow-up period. Parameters associated with a higher probability of short-term worsening were proximity of the baseline EDSS score to 4.5 and duration of MS less than 20 years.
CONCLUSION: Baseline EDSS and duration of MS must be considered in the design of clinical trials of progressive MS.

Entities:  

Mesh:

Year:  1996        PMID: 8929158     DOI: 10.1001/archneur.1996.00550040093018

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  13 in total

1.  Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease.

Authors:  S J Pittock; R L McClelland; S J Achenbach; F Konig; A Bitsch; W Brück; H Lassmann; J E Parisi; B W Scheithauer; M Rodriguez; B G Weinshenker; C F Lucchinetti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

Review 2.  Aggressive multiple sclerosis: proposed definition and treatment algorithm.

Authors:  Carolina A Rush; Heather J MacLean; Mark S Freedman
Journal:  Nat Rev Neurol       Date:  2015-06-02       Impact factor: 42.937

3.  Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.

Authors:  João Carlos Correia de Sa; Laura Airas; Emmanuel Bartholome; Nikolaos Grigoriadis; Heinrich Mattle; Celia Oreja-Guevara; Jonathan O'Riordan; Finn Sellebjerg; Bruno Stankoff; Karl Vass; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

4.  Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts.

Authors:  C Liu; L D Blumhardt
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

5.  The role of the cerebellum in multiple sclerosis.

Authors:  Katrin Weier; Brenda Banwell; Antonio Cerasa; D Louis Collins; Anne-Marie Dogonowski; Hans Lassmann; Aldo Quattrone; Mohammad A Sahraian; Hartwig R Siebner; Till Sprenger
Journal:  Cerebellum       Date:  2015-06       Impact factor: 3.847

Review 6.  An Update on the Measurement of Motor Cerebellar Dysfunction in Multiple Sclerosis.

Authors:  Katherine Hope Kenyon; Frederique Boonstra; Gustavo Noffs; Helmut Butzkueven; Adam P Vogel; Scott Kolbe; Anneke van der Walt
Journal:  Cerebellum       Date:  2022-06-27       Impact factor: 3.648

Review 7.  Endogenous Neural Stem Cell Mediated Oligodendrogenesis in the Adult Mammalian Brain.

Authors:  Daniel Z Radecki; Jayshree Samanta
Journal:  Cells       Date:  2022-07-02       Impact factor: 7.666

8.  Interferon beta in secondary progressive multiple sclerosis : daily clinical practice.

Authors:  Jordi Río; Mar Tintoré; Carlos Nos; Neus Téllez; Ingrid Galán; Raul Pelayo; Xavier Montalban
Journal:  J Neurol       Date:  2007-03-14       Impact factor: 4.849

9.  Purkinje cell loss in experimental autoimmune encephalomyelitis.

Authors:  Allan MacKenzie-Graham; Seema K Tiwari-Woodruff; Gaurav Sharma; Cynthia Aguilar; Kieumai T Vo; Lauren V Strickland; Laurie Morales; Boma Fubara; Melanie Martin; Russell E Jacobs; G Allan Johnson; Arthur W Toga; Rhonda R Voskuhl
Journal:  Neuroimage       Date:  2009-07-06       Impact factor: 6.556

10.  Understanding tremor in multiple sclerosis: prevalence, pathological anatomy, and pharmacological and surgical approaches to treatment.

Authors:  Andrés Labiano-Fontcuberta; Julián Benito-León
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.